Diosynth Biotechnology has signed an agreement with Talecris Biotherapeutics for process development and cGMP production of clinical trial material for a specific form of recombinant Plasminogen. Recombinant Plasminogen is an intermediate material used in the manufacture of recombinant Plasmin, a second-generation therapy Talecris is developing for ophthalmic and thrombolytic indications. “We are pleased to have the opportunity to work with Talecris, a dynamic, global company with...